Hims & Hers Health Inc. (HIMS) stock surged 5.15% in Tuesday's pre-market session, following Morgan Stanley's initiation of coverage on the telemedicine company with an Overweight rating.
Morgan Stanley analysts see significant growth potential for the company, which provides direct-to-consumer healthcare services, including prescriptions and over-the-counter products. The brokerage firm set a price target of $26.77 on Hims & Hers Health, implying an upside of over 50% from the stock's current levels.
The bullish initiation from Morgan Stanley has fueled investor optimism about Hims & Hers Health's prospects, driving the stock's strong pre-market rally. The company's innovative telehealth model and growing product portfolio have positioned it well to capitalize on the burgeoning digital healthcare market.
Comments